Studies have shown that including an information leaflet in the drug package may help bridge the information gap between healthcare professionals and patients and improve patient knowledge about drugs.[@b1-asm-3-192]--[@b4-asm-3-192] Pharmacists and physicians also consider these inserts as handy references for drug information, especially when standard information resources are not accessible.[@b5-asm-3-192] There is published data addressing drug information in general[@b6-asm-3-192]--[@b9-asm-3-192] and the readability of patient information provided in package inserts.[@b2-asm-3-192],[@b10-asm-3-192]-- [@b11-asm-3-192] Very little research, however, especially in the Middle East and Arabian Gulf, has addressed the issue of documenting differences in key aspects of drug information among different marketed generic products of the same drug. In addition, little research has assessed the quality of manufacturer-provided prescribing information. Over 5500 pharmaceutical products are registered in the Kingdom of Saudi Arabia.[@b12-asm-3-192] The Regulation of Registration Act, last amended in 1989, sets requirements for manufacturer package inserts of pharmaceutical products registered in the Kingdom.[@b13-asm-3-192]

This report describes the methods and findings of an observational study that assessed the quality of written prescribing information for selected generic drugs that are marketed in Saudi Arabia and manufactured in various countries of the Middle East. The primary objective of this study was to assess the correctness and completeness of information pertaining to indications, dosage, cautions/contraindications, side effects and drug interactions presented in package inserts as compared to a world-renowned reference in drug information. Secondary objectives included pointing out the deficiencies in the quality and quantity of manufacturer-provided information that could be misleading to patients, patient caregivers and prescribers, as well as providing recommendations based on study observations to key regulatory agencies in Saudi Arabia.

Methods
=======

Five drugs were selected for the study from among those meeting the following criteria: 1) the drug is widely used and well known, 2) has several indications, 3) has at least 4 generics registered in Saudi Arabia that are manufactured in the Middle East, 4) ranked in the top 30 drugs in terms of global sales in 2004 and 5) covered therapeutic areas of high worldwide relevance in terms of mortality and morbidity.[@b14-asm-3-192] The selected drugs were atenolol, fluoxetine, ciprofloxacin, metformin and omeprazole.

Written information material, approved by the Saudi Ministry of Health and by the respective regulatory authorities of the countries of manufacture, were collected from pharmacies in Saudi Arabia in May 2005 for the different generics. Written materials were obtained in the form of package inserts prepared by the company holding the marketing authorization.

A total of 37 package inserts for generic products registered in Saudi Arabia and manufactured in the Middle East for atenolol (6 inserts), fluoxetine (4 inserts), ciprofloxacin(11 inserts), metformin(7 inserts), and omeprazole(9 inserts) were collected. Information contained under the following section headings: indications, dosage, cautions/contraindications, side effects, and drug interactions, was compared to that presented in the British National Formulary (BNF 49, March 2005) and the package insert of the brand product marketed in Saudi Arabia. The BNF was used as a reference as it has a worldwide reputation for being complete, independent, reliable, and practice-oriented as a source of drug information. Though not contemporary to the package inserts' publication dates, which ranged between 1996 and 2003, this recent BNF edition served the purpose of identifying requirements for updating prescribing information of products currently on the market. We developed a checklist for each drug, each of which had a varying number of drug information indicators: atenolol (55 indicators) ciprofloxacin (88 indicators), fluoxetine (63 indicators), metformin (32 indicators), and omeprazole (54 indicators) ([Table 1](#t1-asm-3-192){ref-type="table"}). The drug information indicators, detailed in [Table 2](#t2-asm-3-192){ref-type="table"}, were selected based on the presence of the information statements in both the BNF and brand product label. For the side effects section heading, only those side effects that were frequent and severe were included. To be considered frequent, side effects had to be reported as appearing in at least 1% of patients, according to the American Hospital Formulary Service 2005.[@b15-asm-3-192] To be considered severe, side effects had to fit the criteria published by the WHO Collaborating Center for International Drug Monitoring, Uppsala, Sweden.[@b16-asm-3-192] Caution and contraindications section headings were combined under one entity in the statistical analysis. Statements found in the collected materials that were not documented in the BNF or brand package insert were disregarded from a statistical perspective, but incorrect statements are pointed out in the results and discussion sections. The statistical analysis was done in terms of frequencies.

Results
=======

Results are expressed in terms of the percentage of correct indicators present in the package inserts compared to the number of indicators that should be present as per the BNF and brand product label ([Table 3](#t3-asm-3-192){ref-type="table"}). The results indicate substantial disagreement in information between generic package inserts and the comparator references. A cumulative average of 63±16% of drug information indicators were found to be correctly stated in package inserts of the study generics. Section headings with the least conformity with BNF data were those related to dosage (57±28%) and side effects (54±30%). An average of 70±22%, 70±20% and 63±30% of drug information indicators pertaining to indications, cautions/contraindications and drug interactions, respectively, were correctly documented in the package inserts of study generics.

Particular deficiencies were noted in information related to doses in pediatrics and required dosage adjustments in patients with renal/liver impairment. Only two ciprofloxacin generics indicated the possibility of its use in children with cystic fibrosis and included the respective dosing. There was also inaccurate information pertaining to the dose range of fluoxetine in depression; in general, doses were not indication-specific (e.g., doses for bulimia and depression). Moreover, an incorrect maximum dose was indicated in one of the ciprofloxacin generics.

There were deficiencies in the indications section related to both the quantity and quality of written information. Out of 11 ciprofloxacin generics, only one stated anthrax infection as an indication. Only one metformin generic indicated the possibility of its use in combination with insulin. None of the omeprazole generics indicated use and dosage of the drug in severe ulcerating reflux esophagitis in pediatric patients. Certain generics contained indications that were not approved; these included hyperkinetic heart syndrome with atenolol and treatment of atypical mycobacterium with ciprofloxacin.

As for the cautions and contraindications section headings, certain cautions were stated under contraindications, and vice versa. This was observed in the ciprofloxacin package insert, where use in patients less than 18 years old was stated as a contraindication rather than a precaution. This may relate to the lack of updating of the prescribing information, which has been modified in recent years to utilize this drug in certain specific pediatric disease states (e.g. cystic fibrosis, anthrax infection) where benefits outweigh the risks of treatment. Moreover, recent safety data with regard to the risk of suicidal behaviour with fluoxetine was documented in only one of the reviewed package inserts. A serious drug interaction, metformin with contrast media, was not included in either the cautions or the drug interactions section of one of the metformin generics.

Of the package inserts reviewed in the study, only 60% indicated a publication date.

Discussion
==========

An international comparative study analysed the variability in 78 written drug information materials in 26 different countries for three drugs.[@b17-asm-3-192] The results showed substantial disagreement in the materials available to prescribers and patients in different countries. Disagreement was even found within a single country when written materials from different brands of the same drug were compared. The majority of the cases studied were related to products of the same mother company worldwide. That study suggested that there is an urgent need to increase information agreement between materials on drugs at the national level by measures such as requiring that prescribing information for all pharmaceutical equivalents be the same as that approved for a reference drug. A study conducted in Saudi Arabia in 1991 compared package inserts of 10 non-steroidal anti-inflammatory drugs marketed in Saudi Arabia by different companies with the US PDR reference. The comparison was based on the number of words, presence/absence of section headings, and other differences between the information in the package insert and the PDR as well as the Ministry of Health package insert requirements as required by the Registration Act in Saudi Arabia. The study showed variation in both the amount and type of information contained in Saudi-marketed products as compared with the US PDR. Moreover, section headings on possible adverse reactions or drug-drug interactions and the date of revision of the package insert were not mentioned in any of the Saudi-manufactured products.[@b5-asm-3-192] Bjerrum et al[@b18-asm-3-192] examined sources of inconsistency and diverging information in product information leaflets of different brands of generically identical drugs marketed in Denmark. Diverging information about indications for drug use, adverse effects, drug-drug interactions and precautions, as well as considerations concerning pregnancy and breastfeeding resulted in patient confusion, which may have lead to reduced compliance, as measured by the number of inquiries to pharmacies. The study concluded that initiatives should be taken to coordinate information in patient leaflets covering the same generic product.[@b18-asm-3-192]

Another study conducted in Japan evaluated drug information in package inserts and interview forms according to necessity and importance for 324 generic drugs. Generics were found to have 25.3±18.7% to 46.1±14.2% of the information in the product labeling of brand name drugs when products were compared for quantity of information by formulation. Comparison according to manufacturer returned a larger range of variation, 14.4±8.6% to 64.3±14.2%. These data revealed that manufacturer differences play a large role in the provision of drug information. Generic drugs were found to have insufficient information on clinical data, pharmacokinetics, safety, side effects and non-clinical tests.[@b19-asm-3-192]

Key observations in our study include the inaccuracy and incompleteness of the provided prescribing information in reviewed package inserts. The main reason is that information is outdated in many package inserts, especially for some that were initially published years ago (publication dates ranged between 1996 and 2003). This finding indicates the need to enforce requirements for regular updating of drug information in package inserts and to indicate the last revision date through an amendment of the Saudi Regulation of Registration Act to address these issues.

The incorrectness and lack of scientific reliability of the prescribing information, such as inappropriate doses or indications, is misleading to prescribers and pharmacists who consider package inserts as alternative references, especially in developing countries. Incompleteness of safety information whether it be side effects or cautions/contraindications is not acceptable. From a patient safety standing, the information should be complete to avoid any misadventures.

The correctness and completeness of information varied among manufacturers, with some being more consistent in presenting reliable information than others ([Table 3](#t3-asm-3-192){ref-type="table"}). Accordingly, manufacturers should be notified of the need to improve the quality of their products' package inserts and upgrade the presentation of their data, and national authorities are urged to be proactive in this regard and implement standards.

This study, with its small sample size given the number of generics that have flooded the Saudi Arabian market, identifies key findings that may only be the tip of the iceberg. Our results indicate that national authorities should implement appropriate measures aimed at removing misleading and incorrect information in package inserts, which should be the same among generics, as well as incorporating crucial prescribing information, which was found to be missing. Package inserts should be rendered a reliable reference to promote patient safety and assist healthcare providers. Moreover, national authorities in the Middle East and Arabian Gulf should strengthen collaboration and information interchange among each other and with international agencies, such as the World Health Organization, to maintain common quality standards for delivering information through package inserts of generic products.

###### 

Number of drug information indicators for each of five selected drugs.

  Drug            Indications   Dosage   Cautions/Contraindications   Side Effects   Drug Interactions   Total
  --------------- ------------- -------- ---------------------------- -------------- ------------------- -------
  Atenolol        4             4        25                           13             9                   55
  Ciprofloxacin   11            9        17                           33             18                  88
  Fluoxetine      4             7        14                           27             11                  63
  Metformin       3             2        10                           5              12                  32
  Omeprazole      13            14       6                            17             4                   54

###### 

Detailed drug information indicators for five studied drugs based on statements in the British National Formulary (BNF) and brand package inserts.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Atenolol (55 indicators)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Indications and Dosage

  Hypertension: 50 to 100 mg daily\
  Angina pectoris: 100 mg daily or divided twice daily\
  Arrhythmia: 50 to 100 mg daily\
  Early intervention within 12 hours of myocardial infarction: intravenous over 5 minutes, 5 mg, then oral, 50 mg after 15 minutes, 50 mg after 12 hours, then 100 mg daily

  Cautions

  Renal impairment (moderate/severe): reduce dose; pregnancy: may cause intra-uterine growth restriction, neonatal hypoglycemia, and bradycardia; breast feeding: monitor infant, possible toxicity; stable/unstable heart failure/poor cardiac reserve; asthma; diabetes: modifies tachycardia of hypoglycemia; do not discontinue abruptly in patients with ischemic heart disease; risk of precipitating heart failure when beta-blockers and verapamil are used together in established ischemic heart disease; first-degree AV block; portal hypertension; history of obstructive airways disease; myasthenia gravis; history of hypersensitivity---may increase sensitivity to allergens; may reduce response to adrenaline; Prinzmetal's angina; masks signs of thyrotoxicosis

  Contraindications

  Uncontrolled heart failure; marked bradycardia; hypotension; sick sinus syndrome; second- or third- degree AV block; cardiogenic shock; metabolic acidosis; severe peripheral arterial disease; pheochromocytoma (apart from specific use with alpha-blockers)

  Side Effects

  Bradycardia; deterioration of heart failure; postural hypotension; conduction disorders; bronchospasm; peripheral vasoconstriction; gastrointestinal effects; fatigue; sleep disturbances; rashes/dry eyes; nightmares/psychosis/hallucinations; visual disturbances; exacerbation of psoriasis

  Drug Interactions

  Verapamil; diltiazem; nifedipine; digoxin; sympathomimetics; disopyramide; NSAIDs; anesthetics; clonidine
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ciprofloxacin (88 indicators)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Indications and Dosage

  respiratory-tract infections: 250--750 mg twice daily\
  Urinary-tract infections: 250--500 mg twice daily (100 mg twice daily for 3 days in acute uncomplicated cystitis in women)\
  Chronic prostatitis: 500 mg twice daily for 28 days\
  Gonorrhea: 250mg or 500 mg as a single dose\
  Pseudomonal lower respiratory-tract infection in cystic fibrosis: 750 mg twice daily\
  Child 5--17 years: up to 20 mg/kg twice daily (max. 1.5 g daily)\
  Surgical prophylaxis: 750 mg 60--90 minutes before procedure\
  Anthrax (treatment and post-exposure prophylaxis): 500 mg twice daily; child 30 mg/kg daily in 2 divided doses (max. 1g daily)\
  Gastro-intestinal system (including typhoid fever)\
  Bone and joint infection\
  Skin infection\
  Sepsis

  Cautions

  Epilepsy or conditions that predispose to seizures; G6PD deficiency; myasthenia gravis (risk of exacerbation); children or adolescents (arthropathy has developed in weight-bearing joints in young animals); tendon damage: tendon rupture may occur within 48 hours of starting treatment; elderly patients are more prone to tendinitis; the risk of tendon rupture is increased by the concomitant use of corticosteroids; if tendinitis is suspected discontinue immediately; exposure to excessive sunlight should be avoided (discontinue if photosensitivity occurs); avoid excessive alkalinity of urine and ensure adequate fluid intake (risk of crystalluria); renal impairment: moderate: half normal dose; pregnancy: avoid; breast-feeding: avoid---high concentrations in breast milk; discontinue if psychiatric, neurological or hypersensitivity reactions occur; may impair performance of skilled tasks (e.g. driving)

  Contraindications

  History of tendon disorders related to quinolones use; hypersensitivity

  Side Effects

  Dysphagia; tachycardia; edema; hot flushes; sweating; movement disorders; tinnitus; vasculitis; tenosynovitis; erythema nodosum; hemorrhagic bulla; hyperglycemia; gastrointestinal effects; antibiotic-associated colitis; Stevens-Johnson syndrome/toxic epidermal necrolysis; anorexia; increase in blood urea and creatinine; drowsiness; restlessness; asthenia; depression; hallucinations; photosensitivity; hypersensitivity reactions; blood disorders; disturbances in vision, taste, hearing and smell; angioedema; arthralgia/myalgia; tendon inflammation and damage; hemolytic anemia; renal failure; interstitial nephritis; hepatic dysfunction

  Drug Interactions

  Antacids; calcium salts; coumarins; dairy products; glibenclamide; iron; opioid analgesics; phenytoin; probenecid; sucralfate; theophylline; cyclosporine; NSAIDs; zolmitriptan; estrogens; didanosine; diazepam; metoclopramide
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Fluoxetine (63 indicators)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Indications and Dosage

  Depressive illness: 20--60 mg daily; (max. 80 mg daily)\
  Bulimia nervosa: 60 mg daily\
  Obsessive compulsive disorder: 20--60 mg daily\
  Premenstrual dysphoric syndrome: 20 mg daily\
  Child and adolescent\<18: not recommended\
  Discontinue if no improvement after 10 weeks

  Cautions

  Renal impairment: (moderate): give on alternate days (severe): avoid; reduce dose or avoid in severe liver disease; pregnancy: use only when required; breast-feeding: avoid; patients with epilepsy; history of mania; cardiac disease; weight loss; diabetes mellitus; risk of suicidal behavior with young adults; hemorrhage; impair performance of skilled tasks

  Contraindications

  Use during the panic phase; use with MAOI

  Side Effect

  Anorexia with weight loss; gastro-intestinal effects; hypersensitivity reactions/anaphylaxis; angioedema; arthralgia/myalgia; photosensitivity; nervousness/anxiety/insomnia; tremor; drowsiness; urinary retention; sweating; hyponatremia/inappropriate ADH secretion; hypomania/mania; movement disorders/dyskinesia; visual disturbance; hallucinations; convulsion; galactorrhea; sexual dysfunction; blood sugar change; fever; serotonin syndrome; abnormal bleeding/vaginal bleeding on withdrawal/GI hemorrhage; ecchymoses; blood dyscrasias: pancytopenia/thrombocytopenia/anemia; violent behavior; hair loss

  Drug Interactions

  Should not be started until 2 weeks after stopping a MAOI; warfarin/St. John's wort; tricyclic antidepressants; antiepileptics; lithium; serotonergics: sumatriptan, tramadol; tryptophan; electrocunvulsive therapy; flecainide; vinblastine; MAOI should not be started until at least 5 weeks after fluoxetine is stopped
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Metformin (32 indicators)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Indications and Dosage

  Diabetes mellitus; with insulin; with sulfonylureas\
  Initially 500 mg with breakfast × 1 week then 500 mg with breakfast/dinner x1 week then 500 mg with breakfast/lunch/dinner\
  Maximum dose: 3g divided three times daily

  Caution

  Measure serum creatinine before treatment and once or twice annually during treatment

  Contraindications

  Renal impairment: (mild) avoid due to increased risk of lactic acidosis; ketoacidosis; hepatic impairment: withdraw if tissue hypoxia likely; use of iodine-containing X-ray contrast media (do not restart metformin until renal function returns to normal); use of general anesthesia/surgery (suspend metformin 2 days beforehand and restart when renal function returns to normal); pregnancy: avoid and substitute insulin; breast feeding: avoid; heart failure; respiratory insufficiency

  Side-effects

  Anorexia; gastrointestinal side effects; metallic taste; rarely lactic acidosis (withdraw treatment); decreased vitamin-B12 absorption

  Drug Interactions

  Angiotensin-converting enzyme inhibitors; alcohol; anabolic steroids; antidepressants; antihistamines; beta-blockers; corticosteroids; diazoxide; diuretics; hormone antagonists; estrogens/progesterone; testosterone
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Omeprazole (54 indicators)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Indications and dose

  Adult\
  Benign duodenal ulcer: 20 mg daily × 4 weeks\
  Benign gastric ulcer: 20 mg daily × 8 weeks\
  Maximum dose: 40 mg daily\
  Ulcer Maintenance: 20 mg daily\
  Prevention of relapse in duodenal ulcer: 10 mg-20 mg daily\
  NSAID-associated ulcer treatment: 20 mg daily × 4--8weeks\
  NSAID-associated ulcer prophylaxis in patients with history of ulcer/dyspeptic syndrome): 20 mg daily\
  Zollinger-Ellison syndrome: Initial: 60 mg daily; usual: 20--120 mg daily (\>80 mg divide twice daily)\
  GERD Treatment: 20--40 mg daily × 4--8 weeks\
  GERD maintenance: 20 mg daily\
  Acid reflux disease -Reflux esophagitis (long-term management): 10--20 mg daily\
  Acid-related dyspepsia: 10--20 mg daily × 2--4 weeks\
  H. Pylori: 20 mg twice daily or 40 mg daily × 1--2 weeks\
  Child \>2 years\
  Severe ulcerating reflux esophagitis: 0.7--1.4 mg/kg daily × 4--12 weeks (max: 40 mg daily)

  Cautions

  Liver disease: not more than 20 mg daily should be needed; pregnancy: toxicity in animal studies; lactation: avoid---no information available; may mask the symptoms of gastric cancer; presence of 'alarm features' (dyspepsia/bleeding/dysphagia/recurrent vomiting/weight loss); rule out gastric malignancy before treatment

  Side Effects

  Paresthesia; vertigo; alopecia; gynecomastia; stomatitis; encephalopathy in severe liver disease; hyponatremia; reversible confusion; agitation; hallucinations in the severely ill; increase the risk of gastro-intestinal infections; myalgia/arthralgia; skin reactions; gastro-intestinal disturbance; headache; dizziness; hematological: leucopenia/thrombocytopenia/agranulocytosis

  Drug Interactions

  Ketoconazole; diazepam; warfarin; phenytoin
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Correctness and completion of information in generic package inserts vs. indicators based on the BNF and brand product label.[1](#tfn2-asm-3-192){ref-type="table-fn"}

  Generic formulations   Indications (%)   Dosage (%)   Cautions (%)   Side Effects (%)   Drug Interactions (%)   Mean (%)   ±SD   Company
  ---------------------- ----------------- ------------ -------------- ------------------ ----------------------- ---------- ----- ---------------
  Atenolol                                                                                                                         
   Canar                 100               25           72             77                 85                      72         28    Tabuk
   Glormin               100               100          80             66                 100                     89         16    Global Pharma
   Hypoten               50                25           79             38                 56                      50         20    Hikma
   Normoten              100               50           50             46                 33                      56         26    Al Jazeera
   Tenol                 100               100          58             85                 89                      86         17    Saudi-Kuwait
   Tensotin              75                75           88             85                 89                      82         7     Julphar
  Ciprofloxacin                                                                                                                    
   Ciflox                91                67           82             97                 83                      84         11    Saudi-Kuwait
   Ciprocin              64                22           47             23                 39                      39         18    EPICO
   Ciprodar              55                33           35             42                 44                      42         9     Dar Al Dawa
   Ciproflacin           64                22           47             23                 28                      37         18    Ram Pharma
   Ciproflox             64                44           41             42                 22                      43         15    Al Arabia
   Ciprogen              91                89           53             87                 56                      75         19    Riyadh Pharma
   Cipromax              73                33           35             94                 28                      53         29    Spimaco
   Ciproxen              55                22           35             13                 39                      33         16    Jamjoom
   Floxacin              73                33           65             35                 61                      53         18    SAJA
   Quinox                64                44           29             35                 56                      46         14    Tabuk
   Sarf                  82                78           82             87                 72                      80         6     Julphar
  Fluoxetine                                                                                                                       
   Evrex                 100               85           75             37                 45                      68         27    Al Jazira
   Flozak                100               71           88             44                 73                      75         21    Riyadh Pharma
   Flutin                75                28           69             96                 82                      70         26    Julphar
   Linz                  75                71           69             37                 64                      63         15    Tabuk
  Metformin                                                                                                                        
   Dialon                67                50           90             80                 92                      76         17    Julphar
   Diaphage              67                50           80             100                75                      74         18    UPM
   Formit                67                50           80             80                 8                       57         30    Spimaco
   Glucare               33                100          76             80                 42                      66         28    Al Jazira
   Metaphage             33                100          60             40                 33                      53         28    Saudi-Kuwait
   Metfor                33                50           70             20                 42                      43         19    Tabuk
   Riyadhformin          100               100          100            60                 25                      77         34    Riyadh Pharma
  Omeprazole                                                                                                                       
   Aciloc                69                71           67             87                 100                     79         14    Jamjoom
   Gastrozole            62                64           83             33                 100                     68         25    Riyadh Pharma
   Hyposec               30                36           83             7                  100                     51         39    Ram Pharma
   Omedar                38                21           83             40                 100                     56         33    Dar Al Dawa
   Omeprex               46                29           83             13                 100                     54         36    SAJA
   Omeral                92                93           100            33                 100                     84         29    Al Jazeera
   Omiz                  54                14           67             40                 75                      50         24    Tabuk
   Oprazole              77                79           100            7                  0                       53         46    Hikma
   Rizek                 85                86           100            100                100                     94         8     Julphar
  Mean                   70                57           70             54                 63                      63               
  SD(+/−)                22                28           20             30                 30                      16               

SD= standard deviation.

Results calculated as % (observed number of correct indicators/actual number of indicators in [Table 1](#t1-asm-3-192){ref-type="table"})
